Rudolf Lucas

USPTO Granted Patents = 11 (Patent Applications = 3)

CIPO Patents = 4

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 2.6

ph-index = 2

Forward Citations = 6(Granted Patents)

Location History:

Antwerp, BE (2014)
Martinez, GA (US) (2017 - 2020)
Aartselaar, BE (2007 - 2021)
Vienna, AT (2023)

Company Filing History:

9 out of 11

Apeptico Forschung Und Entwicklung Gmbh

Augusta University Research Institute, Inc.

patents

where one patent can have more than one assignee

Years Active: 2007-2023

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11639368 - Method for preventing and treating hyperpermeability (2023-05-02),

2. 11161881 - Composition comprising a peptide and an inhibitor of viral neuraminidase (2021-11-02),

3. 10711041 - Lyophilisate containing a cyclic peptide of formula X-GQRETPEGAEAKPWY-X (2020-07-14),

4. 10344055 - Composition comprising a peptide and an inhibitor of viral neuraminidase (2019-07-09),

5. 10201588 - Materials and methods of treating dyslipidemia (2019-02-12),

6. 9802985 - Pharmaceutical composition for treatment of the pulmonary form of altitude sickness caused by lack of oxygen and reduced air pressure (2017-10-31),

7. 9359419 - Treatment of vascular complications of diabetes (2016-06-07),

8. 8754049 - Organic compound for the regulation of vectorial ion channels (2014-06-17),

9. 8501679 - Cyclic, cystein-free protein (2013-08-06),

10. 8372799 - Reverse protein (2013-02-12),

11. 7258861 - TNF-derived peptides for use in treating oedema (2007-08-21),

Title: The Innovations of Rudolf Lucas

Introduction

Rudolf Lucas is a notable inventor based in Aartselaar, Belgium. He has made significant contributions to the field of biotechnology, particularly in the development of peptides for medical applications. With a total of 11 patents, his work has the potential to impact various therapeutic areas.

Latest Patents

Among his latest patents, Rudolf Lucas has developed a method for preventing and treating hyperpermeability. This involves a peptide consisting of 7-17 adjacent amino acids, which includes the hexamer TXEXXE. The peptide is cyclized and does not exhibit TNF receptor binding activity, making it suitable for the prevention and treatment of hyperpermeability in epithelial and endothelial cells. Another significant patent describes a composition that includes a peptide and an inhibitor of viral neuraminidase. This composition also features a cyclized peptide with the same hexamer structure, ensuring it does not bind to TNF receptors.

Career Highlights

Rudolf Lucas has worked with several companies throughout his career, including Apeptico Forschung und Entwicklung GmbH and Innogenetics N.V. His experience in these organizations has allowed him to refine his expertise in peptide research and development.

Collaborations

Rudolf has collaborated with notable individuals in his field, including Bernhard Fischer and Hendrik Fischer. These partnerships have contributed to the advancement of his innovative projects.

Conclusion

Rudolf Lucas stands out as a prominent inventor in the biotechnology sector, with a focus on peptide-based solutions for medical challenges. His contributions continue to pave the way for future innovations in the field.

This text is generated by artificial intelligence and may not be accurate.